INS and neoplasm: Modest ↑ in plasma insulin (no effect on glucose)PI3K pathway inhibition in hair & skin across doses including MTDRobust PI3K pathway inhibition across diverse tumor types: - ↓ pAktS473 (50–90%), ↓ pAktT308 (50–80%), ↓ p4EBP1 (60–90%)MAPK pathway inhibition in tumors: ↓ pERK (40–80%)